Latest News - Multiple Sclerosis & Immune Disorders

Tuesday, December 18, 2018

New Drug Application Submitted for Therapy for Multiple Sclerosis

A New Drug Application (NDA) has been submitted to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for treating relapsing forms of mult…

Read the full story

Monday, December 03, 2018

FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome

The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This is the first FDA approva…

Read the full story

Friday, November 30, 2018

Warning Issued for Possible Stroke Risk When Starting Alemtuzumab

The Food and Drug Administration (FDA) has issued a warning about possible risk of stroke and neurovascular injury for patients starting treatment with alemtuzumab (Lemtrada, Campath; Sanofi-Genzyme, …

Read the full story

Wednesday, November 28, 2018

Biases in Dementia Screening Tools

Brief cognitive tests are useful screening tools for dementia in the primary care setting; however, a study published in the journal Neurology Clinical Practice shows that 3 of the most comm…

Read the full story

Tuesday, November 13, 2018

Possible Therapy for Polio-Like Illness Is Not Effective

In new research on a potential treatment for acute flaccid myelitis, the antidepressant fluoxetine showed no efficacy. The study, published in the November 9, 2018 online issue of Neurology, …

Read the full story

Tuesday, October 23, 2018

New Data Available on Risk of Relapse During Pregnancy for Women With Multiple Sclerosis

Multiple sclerosis (MS) most often affects women of childbearing age, making family planning and management of the disease before, during, and after pregnancy a primary concern for many patients. In 2…

Read the full story

Friday, October 12, 2018

Cladribine Extension Trial and Post Hoc Analysis Shows 10-Year Safety and Efficacy

In data presented at the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany Oct. 10-12, real-world follow up and post-hoc analysis of cladribine (E…

Read the full story

Friday, October 12, 2018

Dimethyl Fumarate Has Low Risk of Progressive Multifocal Leukoencephalopathy, Short Duration of Lymphopenia, and Long-Term Efficacy for Relapsing Multiple Sclerosis

At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany October 10-12, results were reported from an integrated analysis of data from the DEFINE…

Read the full story

Friday, October 12, 2018

Evobrutinib—A First-in-Class Drug—Shows Efficacy in Phase 2 Clinical Trials

October 12, 2018 -- At the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, German October 10-12, results from a double-blind placebo-controlled trial (N…

Read the full story

Thursday, October 11, 2018

Alemtuzumab Has Continued Efficacy for Patients With Multiple Sclerosis After 8 years of Follow-Up

Phase 3 extension studies for alemtuzumab (Lemtrada; Sanofi-Genzyme, Cambridge, MA) has continued efficacy after 8 years of treatment according to results presented at the European Committee on Resear…

Read the full story

Thursday, October 11, 2018

Natalizumab Has Long Term Efficacy and Safety That is Well Controlled With Use of the JCV Index

In results presented at the European Committee on Treatment and Research for Multiple Sclerosis (ECTRIMS) conference in Berlin, Germany, data on the use of natalizumab (NTZ) (Tysabri; Biogen, Cambridg…

Read the full story

Thursday, October 11, 2018

Ocrelizumab Reduces Upper Limb Disability for Patients With Progressive Multiple Sclerosis

October 11, 2018 -- Results from new analysis of the phase 3 ORATORIO study (NCT01194570) were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in…

Read the full story

Wednesday, October 10, 2018

Ozanimod May Have Benefits on Cognition and Annualized Relapse Rate for Patients With Multiple Sclerosis

Results of post hoc analyses of pivotal phase 3 trials assessing the efficacy of the investigational compound ozanimod (Celgene, Summitt, NJ) versus interferon ß-1a (IFN) (Avonex; Biogen, C…

Read the full story

Wednesday, October 10, 2018

Long-Term Efficacy of Ocrelizumab Treatment for People with Relapsing Multiple Sclerosis

Multiple results regarding use of ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) for treatment of patients with multiple sclerosis (MS) were presented today at the European Committee for Tr…

Read the full story

Thursday, September 13, 2018

Fingolimod Effective for Treating Pediatric Patients with Multiple Sclerosis

Complete results from landmark phase 3 PARADIGMS clinical trial (NCT01892722) were published in the New England Journal of Medicine (September 12, 2018). The PARADIGMS trial is the first-ever complete…

Read the full story
Load More